MET Amplification and Efficacy of Nivolumab in Patients With NSCLC

Introduction: MET amplification is an important genetic alteration in NSCLC. Unlike in patients with EGFR and ALK alterations, the efficacy of immune checkpoint inhibitors in patients with MET-amplified NSCLC remains unknown. Methods: An exploratory analysis of a prospective, multi-institutional coh...

Cijeli opis

Bibliografski detalji

Glavni autori:	Katsuhiro Yoshimura, MD, PhD, Yusuke Inoue, MD, PhD, Naoki Inui, MD, PhD, Masato Karayama, MD, PhD, Hideki Yasui, MD, PhD, Hironao Hozumi, MD, PhD, Yuzo Suzuki, MD, PhD, Kazuki Furuhashi, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Noriyuki Enomoto, MD, PhD, Yutaro Nakamura, MD, PhD, Haruhiko Sugimura, MD, PhD, Takafumi Suda, MD, PhD
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2021-11-01
Serija:	JTO Clinical and Research Reports
Teme:	Lung cancer MET Nivolumab Amplification Immune checkpoint inhibitor
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2666364321000989
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!